Brand, T. M., Dunn, E. F., Iida, M., Myers, R. A., Kostopoulos, K. T., Li, C., . . . Wheeler, D. L. (2011). Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab. Landes Bioscience.
Chicago Style CitationBrand, Toni M., Emily F. Dunn, Mari Iida, Rebecca A. Myers, Kellie T. Kostopoulos, Chunrong Li, Chimera R. Peet, i Deric L. Wheeler. Erlotinib Is a Viable Treatment for Tumors With Acquired Resistance to Cetuximab. Landes Bioscience, 2011.
Cita MLABrand, Toni M., et al. Erlotinib Is a Viable Treatment for Tumors With Acquired Resistance to Cetuximab. Landes Bioscience, 2011.
Atenció: Aquestes cites poden no estar 100% correctes.